Atlas Venture Associates IX’s Intellia Therapeutics NTLA Stock Holding History

Atlas Venture Associates IX’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$316K	Hold	10,000	–	–	2.69%	6
2023 Q2	$408K	Hold	10,000	–	–	2.23%	6
2023 Q1	$373K	Hold	10,000	–	–	1.75%	6
2022 Q4	$349K	Hold	10,000	–	–	1.74%	6
2022 Q3	$560K	Hold	10,000	–	–	1.66%	6
2022 Q2	$518K	Hold	10,000	–	–	1.18%	7
2022 Q1	$727K	Hold	10,000	–	–	0.67%	7
2021 Q4	$1.18M	Hold	10,000	–	–	0.52%	7
2021 Q3	$1.34M	Hold	10,000	–	–	0.45%	7
2021 Q2	$1.62M	Sell	10,000 -1,103,376	-99%	-$85.9M	0.28%	7
2021 Q1	$89.4M	Sell	1,113,376 -501,945	-31%	-$33.7M	15.01%	2
2020 Q4	$87.9M	Hold	1,615,321	–	–	13.93%	2
2020 Q3	$32.1M	Hold	1,615,321	–	–	33.22%	1
2020 Q2	$34M	Hold	1,615,321	–	–	36.31%	1
2020 Q1	$19.8M	Hold	1,615,321	–	–	41.77%	1
2019 Q4	$23.7M	Hold	1,615,321	–	–	41.29%	1
2019 Q3	$21.6M	Hold	1,615,321	–	–	35.49%	1
2019 Q2	$26.4M	Hold	1,615,321	–	–	28.28%	1
2019 Q1	$27.6M	Hold	1,615,321	–	–	25.92%	1
2018 Q4	$22M	Hold	1,615,321	–	–	25.39%	1
2018 Q3	$46.2M	Sell	1,615,321 -221,489	-12%	-$6.44M	24.47%	2
2018 Q2	$50.3M	Sell	1,836,810 -442,978	-19%	-$10.7M	22.12%	2
2018 Q1	$48.1M	Sell	2,279,788 -1,300,000	-36%	-$32M	36.34%	1
2017 Q4	$68.8M	Hold	3,579,788	–	–	60.94%	1
2017 Q3	$89M	Sell	3,579,788 -150,000	-4%	-$2.83M	62.83%	1
2017 Q2	$59.7M	Hold	3,729,788	–	–	95.72%	1
2017 Q1	$52.6M	Sell	3,729,788 -700,000	-16%	-$9.39M	100%	1
2016 Q4	$58.1M	Buy	+4,429,788	New	+$66.6M	100%	1

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Atlas Venture Associates IX's NTLA Position: Q3 2023 in Review

Atlas Venture Associates IX held its Intellia Therapeutics (NTLA) position steady in Q3 2023 at 10,000 shares worth $316K. The position accounts for 2.69% of the portfolio, ranked #6.

Atlas Venture Associates IX first reported a position in NTLA in Q4 2016 and has held it in 28 quarters since. The position peaked at $89.4M in Q1 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

Atlas Venture Associates IX held 10,000 shares of Intellia Therapeutics worth $316K as of Q3 2023.
Atlas Venture Associates IX left its Intellia Therapeutics share count unchanged in Q3 2023.
Intellia Therapeutics made up 2.69% of Atlas Venture Associates IX's portfolio in Q3 2023, its #6 holding.
Atlas Venture Associates IX first reported a position in Intellia Therapeutics in Q4 2016 and has held it in 28 quarters since.
Atlas Venture Associates IX's Intellia Therapeutics position peaked at $89.4M in Q1 2021.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on Atlas Venture Associates IX's 13F filing for Q3 2023, filed 13 Nov 2023.